Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Doramapimod
Cat. No.:
OB0225LY-0428
Appearance:
Solid
Purity:
≥98%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Product Overview
Description:
Doramapimod is a small molecule MAPK pathway inhibitor that primarily targets p38 MAPK.
Synonym:
BIRB 796; 285983-48-4; BIRB-796; BIRB 796 (Doramapimod); BIRB796; BIRB-796 BS; BIRB 796 BS; 3-[3-tert-Butyl-1-(4-methylphenyl)-1H-pyrazol-5-yl]-1-{4-[2-(morpholin-4-yl)ethoxy]naphthalen-1-yl}urea; 1-[5-tert-Butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]urea; 1-(3-(tert-Butyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-3-(4-(2-morpholinoethoxy)naphthalen-1-yl)urea
CAS No.:
285983-48-4
Compound CID:
156422
Formula:
C31H37N5O3
Formula Weight:
527.66
Specification
Relative Density:
1.2 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Doramapimod can be used in cell signaling studies to explore the role of p38 MAPK in different biological processes.
Library Information
Targets:
Serine/Threonine kinases
Receptors:
p38 MAPK; p38α; Raf
Pathways:
MAPK; Autophagy
Plate Number:
AOCL-6
Plate Location:
e4
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
20 mg/mL; 37.9 mM
Ethanol Max Solubility:
26.4 mg/mL; 50 mM
ALogP:
5.907
HBA_Count:
4
HBD_Count:
2
Rotatable Bond:
8
